With its launch of chronic myeloid leukemia drug Iclusig, Ariad Pharmaceuticals just topped Wall Street estimates for the quarter and is showing significant promise despite what on the surface appear to be meager numbers.
In this video, health-care analyst David Williamson discusses its potential to continue to surprise investors and beat Wall Street going forward. Watch and find out if Ariad is a stock investors need on their radars.
What could be a slam-dunk for investors is a company working to eradicate the macro trend Warren Buffett called "the tapeworm that's eating at American competitiveness." Find out what Buffett was referring to in our free report: "What's Really Eating at America's Competitiveness." Just click here for free, immediate access.
Follow David on Twitter: @MotleyDavid.
The article Does Ariad's Leukemia Drug Have Hidden Potential? originally appeared on Fool.com.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.